As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.
Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding ...
There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...